After finishing at $147.99 in the prior trading day, Alnylam Pharmaceuticals Inc (NASDAQ: ALNY) closed at $146.62, down -0.93%. In other words, the price has decreased by -$1.37 from its previous closing price. On the day, 610572 shares were traded.
Ratios:
Our goal is to gain a better understanding of ALNY by taking a closer look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 7.57 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 440.21. For the most recent quarter (mrq), Quick Ratio is recorded 2.99 and its Current Ratio is at 3.08.
On December 08, 2023, Wells Fargo started tracking the stock assigning a Equal Weight rating and target price of $171.Wells Fargo initiated its Equal Weight rating on December 08, 2023, with a $171 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Feb 29 ’24 when SHARP PHILLIP A sold 30,000 shares for $151.34 per share. The transaction valued at 4,540,071 led to the insider holds 0 shares of the business.
Greenstreet Yvonne sold 2,932 shares of ALNY for $455,357 on Feb 28 ’24. The Chief Executive Officer now owns 48,128 shares after completing the transaction at $155.31 per share. On Feb 28 ’24, another insider, Garg Pushkal, who serves as the CMO & EVP Dev & Med Affairs of the company, sold 574 shares for $155.30 each. As a result, the insider received 89,145 and left with 8,666 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ALNY now has a Market Capitalization of 18.47B and an Enterprise Value of 17.33B. For the stock, the TTM Price-to-Sale (P/S) ratio is 10.10. Its current Enterprise Value per Revenue stands at 9.48 whereas that against EBITDA is -80.52.
Stock Price History:
Over the past 52 weeks, ALNY has reached a high of $218.88, while it has fallen to a 52-week low of $143.52. The 50-Day Moving Average of the stock is 165.18, while the 200-Day Moving Average is calculated to be 178.53.
Shares Statistics:
The stock has traded on average 844.16K shares per day over the past 3-months and 628.34k shares per day over the last 10 days, according to various share statistics. A total of 125.79M shares are outstanding, with a floating share count of 125.27M. Insiders hold about 0.53% of the company’s shares, while institutions hold 93.69% stake in the company. Shares short for ALNY as of Feb 29, 2024 were 3.04M with a Short Ratio of 3.60, compared to 4.01M on Jan 31, 2024. Therefore, it implies a Short% of Shares Outstanding of 2.41% and a Short% of Float of 3.18%.
Earnings Estimates
Its stock is currently analyzed by 21 different market analysts. On average, analysts expect EPS of -$1.18 for the current quarter, with a high estimate of -$0.27 and a low estimate of -$1.56, while EPS last year was -$1.4. The consensus estimate for the next quarter is -$1.04, with high estimates of -$0.09 and low estimates of -$1.5.
Analysts are recommending an EPS of between -$0.96 and -$5.9 for the fiscal current year, implying an average EPS of -$4.18. EPS for the following year is -$1.76, with 21 analysts recommending between $1.36 and -$4.32.
Revenue Estimates
20 analysts predict $426.51M in revenue for the current quarter. It ranges from a high estimate of $452.3M to a low estimate of $405.65M. As of the current estimate, Alnylam Pharmaceuticals Inc’s year-ago sales were $319.29M, an estimated increase of 33.60% from the year-ago figure. For the next quarter, 20 analysts are estimating revenue of $463.48M, an increase of 45.40% over than the figure of $33.60% in the same quarter last year. There is a high estimate of $565.06M for the next quarter, whereas the lowest estimate is $435.5M.
A total of 24 analysts have provided revenue estimates for ALNY’s current fiscal year. The highest revenue estimate was $2.04B, while the lowest revenue estimate was $1.78B, resulting in an average revenue estimate of $1.85B. In the same quarter a year ago, actual revenue was $1.83B, up 1.00% from the average estimate. Based on 22 analysts’ estimates, the company’s revenue will be $2.33B in the next fiscal year. The high estimate is $2.97B and the low estimate is $1.87B. The average revenue growth estimate for next year is up 25.90% from the average revenue estimate for this year.
